To overcome these limitations, NMR data and pharmacophore modeling of PTX3/FGF2 interaction were used in our laboratory to identify the PTX3-derived small molecule NSC12 as the first orally active pan-FGF trap able to inhibit FGFR activation and tumor growth in various FGF-dependent murine and human tumor models [20,21]. Here, PTX3 is linked to neoplasm.